No benefit of adding docetaxel to ADT+RT in treating localized high-risk or pelvic lymph node only (N1) newly-diagnosed patients

[Tall_Allen]

I updated this with the most recent STAMPEDE trial of adding docetaxel to ADT in what they call "high-risk" patients.

prostatecancer.news/2016/08...

[rosatt1]

Thanks Tall_Allen for supplying up to date data.

[Gabby643]

Thanks T A

[PGDuan]

Thanks for the update on this Tall__Allen. Very timely as many of us face treatment decisions in this situation space. Definitely an area to keep watching for continued updates.

[garyjp9]

Thank you, TA. I agree with the others. Very timely and relevant.

[Ficus238]

Thanks, Tall_Allen! Your experience/insight is why I’m here.

My PSMA PET just confirmed T0 N1 M0. 22 months after a perfect HIFU. PSA was non-detect at 3 months rising steady to 3.6 last week. (Pre HIFU: 4+3 Hopkins; Decipher “low risk”)

Based on Dr. Scholz’s “high indigo” I was preparing for Lupron + Zytiga + Taxotere for max efficacy. Haven’t seen RO/MO yet.

Your posting this study is reassuring and certainly has reduced my apprehension as to what’s to come next! Thank you!